This study evaluates the effect of ivabradine on endothelial function in patients with coronary artery disease (CAD) after complete revascularization with percutaneous coronary angioplasty (PCI). At least 30 days after PCI, patients will be randomized to receive ivabradine 5 mg twice daily or to continue with standard medical therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
70
Ivabradine 5 mg twice daily
Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Campus Bio-Medico University
Rome, RM, Italy
Flow-mediated dilation of the brachial artery
Time frame: 8 weeks
Number of patients with flow-mediated dilation of the brachial artery <7%
Time frame: 8 weeks
Endothelium-independent dilation of the brachial artery
Dilation of the brachial artery after administration of 0.5 mg sublingual nitroglycerin
Time frame: 8 weeks
Correlation between heart rate and flow-mediated dilation of the brachial artery
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.